Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
The expected CAGR for the GLP-1 receptor agonist market leading up to 2030 is 16%
.webp)
Presented for research literature review only Norin A et al
Tirzepatide, the first dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA approved for both conditions, has paved the way for next-generation incretin-based therapies
What was once investigational is now reality
&srotate=0)
10.1111/j.1749-6632.1992.tb39755.x 152 WynnT
Section 7: GSKs Upper Merion Hub: Smart Manufacturing IP and Capital Analysis 7.1 The Investment and Its Strategic Rationale GlaxoSmithKlines manufacturing facility in Upper Merion, Pennsylvania is one of the most thoroughly documented examples of smart factory implementation at commercial pharmaceutical scale
US$ 22.61
US$ 25.75
US$ 25.13
